Clinical trials: Transplant Rejection
Coronary Heart Disease
Post-marketing Study to Collect Safety Data in Heart Transplant Patients Receiving Everolimus
The purpose of this observational protocol is to evaluate the use of everolimus in routine clinical practice for heart transplants. Primary outcome measures: incidence of acute rejection episodes Secondary outcomes: safety
- Trial name
- NCT00134940
- Where
- 6 sites in Austria, Germany
- Volunteers
- 100 people
- Sponsor
- Novartis
Organ Transplant Failure or Rejection, Brain Death
Calcineurin Inhibitor in NEuRoloGically Deceased Donors to Decrease Kidney delaYed Graft Function (CINERGY)
The investigators hypothesize that preconditioning neurologically deceased organ donors with the calcineurin inhibitor tacrolimus will improve short and long-term transplant survival without causing harm.
- Conditions
- Organ Transplant Failure or Rejection, Brain Death, Ischemic Reperfusion Injury
- Trial name
- CINERGY (NCT05148715)
- Testing
- Tacrolimus
- Where
- 9 sites in Canada
- Volunteers
- 414 people
- Sponsor
- Université de Sherbrooke
End-stage Renal Failure, Kidney Graft Rejection
Reference Group Trial for The ONE Study
To investigate the progression of the immunological response in living-donor kidney transplant recipients treated with a standard immunosuppressive regimen.
- Trial name
- NCT01656135
- Testing
- Blood drawing for immune monitoring and questionnaires
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 70 people
- Sponsor
- University of Regensburg
Renal Transplant Rejection
The Effect of Rituximab on the Development of Anti-Donor Antibodies
The aim of the study is to find out if Rituximab, which is an antibody against specific white cells involved in rejection, when combined with standard anti-rejection treatment can more effectively reverse the rejection process.
- Trial name
- NCT00695097
- Testing
- Rituximab, No Rituximab
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of California, San Francisco
Heart Transplant Rejection
Heartsbreath Test for Heart Transplant Rejection
The purpose of this study is to demonstrate and validate a breath test for detection of biomarkers of heart transplant rejection (Grade 2R heart transplant).
- Trial name
- Heartsbreath (NCT01397812)
- Testing
- BreathScanner 1.0, BreathLink
- Where
- 5 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Menssana Research, Inc.
Hematopoietic Stem Cell Transplantation, Graft Failure
Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
The investigators hypothesize that graft rejection after hematopoietic stem cell transplant (HSCT) is primarily driven by interferon gamma, and prophylactic interferon gamma inhibition in high-risk patients will prevent graft…
- Trial name
- NCT07244419
- Testing
- Emapalumab 3 mg/kg, Emapalumab 10 mg/kg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Lung Transplant Rejection
Next Generation Sequencing to Detect Acute Rejection in Lung Transplant Patients.
Lung transplantation is a consolidated treatment in selected patients with end-stage respiratory diseases; however, acute rejection remains an important cause of lung allograft loss and a risk factor for chronic allograft…
- Trial name
- NGS-ACRL (NCT05260372)
- Testing
- Quantification of donor-derived cell-free DNA
- Where
- Italy
- Volunteers
- 55 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Heart Transplant Rejection
Surveillance HeartCare® Outcomes Registry
This is an observational registry to assess the clinical utility of surveillance using HeartCare testing services, in association with clinical care of heart transplant recipients.
- Trial name
- SHORE (NCT03695601)
- Testing
- Standard of Care
- Where
- 67 sites in United States
- Volunteers
- 2,743 people
- Sponsor
- CareDx
Renal Transplant
Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients
The study is designed to compare the pharmacokinetics of generic tacrolimus (Sandoz) to branded tacrolimus (Prograf) in stable renal transplant patients.
- Trial name
- NCT01256294
- Testing
- Generic Tacrolimus, Branded Tacrolimus
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Novartis
Cardiac Graft
Acute Heart Graft Rejection Screening by Cardiac Magnetic Resonance Imaging
Acute heart allograft rejection is a common complication after orthotopic heart transplantation. Primary objective of this study is to assess cardiac MRI as a tool for acute heart graft rejection screening, by detecting changes…
- Trial name
- DRAGON (NCT02400840)
- Testing
- cardiac MRI, gadobenic acid intravenous injection 0.2 ml/kg
- Where
- France
- Sponsor
- University Hospital, Rouen
Kidney Transplant, Kidney Transplantation
Proteogenomic Biomarker Panels in a Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients
There is a need to develop blood and/or urine tests that will help to detect early signs of rejection in people who have had kidney transplant.
- Trial name
- PROGENI-KI (NCT01289717)
- Where
- 5 sites in United States
- Volunteers
- 307 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant Rejection
Treatment of Antibody-Mediated Rejection (ABMR) With CarBel
The purpose of this study is to evaluate the safety of carfilzomib and belatacept, administered with steroids and maintenance immunosuppression, in kidney transplant recipients with donor-specific antibody (DSA)-associated graft…
- Trial name
- CarBel (NCT06918990)
- Testing
- Carfilzomib, Belatacept
- Where
- 11 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant, Kidney Transplant Failure and Rejection
(TNX-1500) in Kidney Transplant Recipients
The primary objective is to investigate the safety of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.
- Conditions
- Kidney Transplant, Kidney Transplant Failure and Rejection, Immunosuppression, Immunosuppression After Kidney Transplantation
- Trial name
- TONIX-1500 (NCT07204080)
- Testing
- TNX-1500, Kidney Transplant
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Ayman Al Jurdi, MD
Kidney Transplant Rejection
TruGraf and TRAC In Pediatrics Study
This is a pilot 3 center prospective study of pediatric renal kidney recipients undergoing protocol biopsies examining the performance of the TruGraf gene expression test in children and adolescents.
- Trial name
- TTIPS (NCT05335538)
- Testing
- Patients monitored with TruGraf and TRAC testing
- Where
- 3 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- Transplant Genomics, Inc.
Transplant Rejection
Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers
The purpose of this study is to determine the effects of belatacept on the pharmacokinetics of caffeine, losartan, omeprazole, dextromethorphan and midazolam
- Trial name
- NCT01766050
- Testing
- Caffeine, Losartan, Omeprazole
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Kidney Transplantation
A Study To Test An Anti-Rejection Therapy After Kidney Transplantation
Kidney transplantation is often successful. However, despite aggressive anti-rejection drug therapy, some patients will reject their new kidney. This study is designed to test two anti-rejection approaches.
- Trial name
- NCT00000936
- Testing
- hOKT3, Oral Cyclosporine, IV Cyclosporine
- Where
- United States
- Volunteers
- 292 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Failure, Chronic
Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
The purpose of this study is to determine whether the anti-T cell antibody, Thymoglobulin is a more effective induction medication than the anti-IL-2R inhibitor daclizumab, in kidney transplant recipients who have a positive…
- Trial name
- NCT00275509
- Testing
- Thymoglobulin, Daclizumab, Plasmapheresis
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Johns Hopkins University
Kidney Transplant Failure and Rejection
A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
The rationale for the current protocol is to collect data from extended follow up in subjects that have received a kidney transplant following imlifidase dosing to provide a better understanding regarding the long-term outcome…
- Trial name
- NCT03611621
- Testing
- Imlifidase
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 31 people
- Sponsor
- Hansa Biopharma AB
Lung Transplant; Complications, Chronic Kidney Diseases
Immunosuppressive Regimen on Changes in Renal Function and Transplant Rejection Rate in Patients With Lung Transplant
This retrospective single-center analyzes the impact of switch of immunosuppressive regimen on renal function and transplant rejection rate in patients with lung transplant.
- Trial name
- NCT03657004
- Where
- Germany
- Volunteers
- 145 people
- Sponsor
- University of Giessen
Kidney Transplant Rejection, Cell-free DNA
Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring
The goal of this observational study is to learn if the donor-derived cell-free DNA (dd-cfDNA) test can assess rejection in kidney transplant recipients. Participants will have blood and urine collected at their study visit.
- Trial name
- NCT07060716
- Testing
- donor-derived cell-free DNA test
- Where
- 10 sites in United States, Germany
- Volunteers
- 125 people
- Sponsor
- Insight Molecular Diagnostics